OraSure Technologies (OSUR) Peer Comparison

$3.69

$-0.02 (-0.54%)

As on 27-Aug-2026 16:00EDT

Market cap

$268 Mln

Revenue (TTM)

$112 Mln

P/E Ratio

--

P/B Ratio

0.8

Div. Yield

0 %

Edit

	OraSure Technologies (OSUR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Market cap ($ Mln)	268	12,753	10,906	9,762	10,222
Revenue ($ Mln)	112	1,505	613	2,589	785
Net Profit ($ Mln)	-49.13	160.59	-188.05	222.40	41.54
Net Margin (%)	-43.70	10.67	-30.68	8.59	5.29
RoE (%)	-14.92	10.86	-28.10	3.04	1.97
Price to Earnings	--	79.35	--	44.47	251.57
Price-To-Book	0.81	8.41	16.38	1.26	4.84

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	OraSure Technologies (OSUR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Operating Revenue	112.41	1,504.87	612.84	2,589.30	785.10
Cost of Revenue	65.90	483.98	127.96	1,245.50	384.30
Gross Profit	48.20	942.44	393.22	1,343.60	347.62
Operating Expenses	96.81	833.56	565.37	1,108.90	335.50
Operating Profit (EBIT)	-50.30	187.34	-80.49	235.00	65.30
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-48.73	203.83	-192.83	350.40	52.15
Provision for Tax	0.39	43.24	-4.79	128.00	10.61
Profit after Tax (Net Income)	-49.13	160.59	-188.05	222.40	41.54
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	OraSure Technologies (OSUR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Shareholder's Funds	317.78	1,530.77	682.49	7,173.90	2,112.03
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	17.66	210.18	135.71	2,116.80	705.49
Current Liabilities	25.12	233.78	102.33	961.30	132.66
Total Liabilities	403.17	1,826.52	893.49	10,576.50	2,949.70

Assets ($ Mln)

	OraSure Technologies (OSUR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Non-Current Assets	137.62	630.60	404.74	7,231.50	1,749.63
Current Assets	222.94	1,344.12	515.78	3,020.50	1,200.55
Total Assets	403.17	1,826.52	893.49	10,576.50	2,949.70
Total Debt*	12.09	212.71	102.84	1,203.70	690.94
Net Current Assets	197.82	1,110.35	413.45	2,059.20	1,067.90

Cashflow ($ Mln)

	OraSure Technologies (OSUR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Cash From Operating Activities	-0.05	238.66	-46.34	532.20	117.42
Cash Flow from Investing Activities	-0.01	-404.59	-77.61	-189.70	-298.47
Cash from Financing Activities	-0.02	26.53	11.89	-283.20	-15.21
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	OraSure Technologies (OSUR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
ROCE (%)	-17.65	11.76	-22.53	8.98	1.79
ROE (%)	-14.92	10.86	-28.10	3.04	1.97
ROA (%)	-11.25	7.95	-18.00	2.02	1.36
EBIT Margin (%)	-45.80	13.63	-30.58	-5.99	9.87
Net Margin (%)	-43.70	10.67	-30.68	8.59	5.29
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	OraSure Technologies (OSUR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Revenue Growth (%)	-18.86	17.55	41.55	1.37	16.49
EBIT Growth (%)	-7.14	17.49	-116.42	-131.06	920.91
Net Profit Growth (%)	3.74	8.72	-102.66	-30.32	400.42
EPS Growth (%)	-0.81	8.12	-96.88	-29.66	394.30
Book Value Growth (%)	-11.32	17.33	-12.65	2.19	2.16

Valuation Ratios

	OraSure Technologies (OSUR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Price / Earnings	-2.52	68.93	-34.59	--	189.42
Price / Book Value	0.51	8.58	9.90	--	4.40
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	0.23	53.25	-43.50	--	55.90
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	OraSure Technologies (OSUR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debt to Equity	0.00	0.00	0.00	0.11	0.26
Short term debt to equity ratio	0.01	0.01	0.00	0.06	0.01
Current Ratio	8.88	5.75	5.04	3.14	9.05
Quick Ratio	7.68	3.86	4.46	2.33	7.64
Interest Coverage	--	157.91	-38.31	8.18	3.36

Operating Efficiency Ratios

	OraSure Technologies (OSUR)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debtors to sales (%)	22.77	12.65	22.67	17.06	20.09
Asset Turnover	0.26	0.74	0.59	0.24	0.26
Receivable days	73.07	46.54	60.95	65.39	72.41
Inventory Days	178.35	331.92	193.84	221.09	146.53
Payable days	40.16	26.16	60.19	37.02	29.05
Cash Conversion Cycle	211.25	352.30	194.60	249.46	189.88

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly